GlobeImmune announces top line results from GS-4774 phase trial
GlobeImmune announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term viral suppression with an oral antiviral treatment. Patients treated with the highest dose of GS-4774 plus OAV did not show a reduction in HBsAg at week 24, the primary endpoint. May 27, 2015